Predictability and outcomes of photoastigmatic keratectomy using the Nidek EC-5000 excimer laser

PURPOSE: To evaluate the effect of astigmatic correction on the accuracy of the myopic and astigmatic correction in patients having photorefractive astigmatic keratectomy (PARK) and in those having photorefractive keratectomy (PRK). SETTING: Specialist excimer laser refractive clinic. METHODS: This prospective consecutive case series comprised 6097 eyes with a preoperative mean spherical equivalent (MSE) of -4.63 diopters (D) +/- 1.95 (SD) (range -0.75 to -13.00 D) and a mean cylinder of -1.13 +/- 0.73 D (range -0.50 to -6.00 D) having PARK with a Nidek EC-5000 excimer laser. Visual and refractive outcomes were assessed 12 months postoperatively and compared with those in 3004 eyes that had spherical PRK. RESULTS: At 12 months, the MSE was -0.02 +/- 0.79 D and the mean cylinder was -0.49 +/- 0.47 D in the PARK group; the MSE was -0.07 +/- 0.66 D in the PRK group. An MSE within +/-0.05 D of emmetropia was achieved by 69.8% and within +/-1.00 D, by 87.9%. The uncorrected visual acuity (UCVA) was 20/20 or better in 42.6% and 20/40 or better in 91.2%. Statistical significance (P <.001, analysis of variance) was achieved for MSE, sphere, cylinder, haze, and visual acuity (best corrected [BCVA] and UCVA) based on the preoperative cylinder. The loss of BCVA varied from 1.1% to 5.8% depending on the degree of astigmatism treated. Accuracy varied with the attempted myopic correction and the attempted astigmatic correction. CONCLUSIONS: Excimer laser PARK was an effective treatment for compound myopic astigmatism, but predictability decreased and complications increased as the attempted astigmatic correction increased.     

Anterior corneal surface after Nidek EC-5000 multipass and multizone photorefractive keratectomy for myopia

PURPOSE: To evaluate the correlation between the presence of irregularities in corneal ablation and the number of ablation zones with multipass and multizone photorefractive keratectomy (PRK). METHODS: The differential maps obtained from corneal topography performed before and 1 month after PRK in 62 eyes that had undergone PRK with the Nidek EC-5000 excimer laser were assessed for irregularities. PRK treatment ranged from -1.00 to -16.00 D (mean -5.25 +/- 2.72 D), and the number of zones ranged from one to five. RESULTS: Of 62 differential maps, 27 had an irregular pattern according to the Hersh classification, with a non-significant correlation with the number of treatment zones (chi2 = 5.09, P >.1). CONCLUSION: Our results suggest that corneal topography irregularities arising from multizone PRK were not related to the amount of treatment or to the number of ablation zones.     

Hyperopic laser in situ keratomileusis with the Nidek EC-5000 excimer laser

OBJECTIVE: To evaluate the efficacy, safety, and predictability of hyperopic laser in situ keratomileusis (H-LASIK) using modified software. DESIGN: Retrospective, noncomparative case series. PARTICIPANTS: The first 72 consecutive eyes of 44 patients with up to +5.00 diopters (D) hyperopia. INTERVENTION: Hyperopic LASIK using the Automatic Corneal Shaper (ACS; Chiron Vision, Claremont, CA) and the Nidek EC-5000 excimer laser (Nidek, Tokyo, Japan). MAIN OUTCOME MEASURES: Uncorrected visual acuity, manifest spherical equivalent (MSE), best-corrected visual acuity (BCVA), and complications were studied. RESULTS: At 6 months, in the low hyperopia group (<3.00 D), mean MSE was +0.30 +/- 0.71 D, with 88.9% eyes within 1 D of emmetropia compared with +1.09 +/- 0.92 D and 51.8% within 1 D of emmetropia in the moderate hyperopia group (> or =3.00 D; P = 0.003). Uncorrected visual acuity was 20/40 or better in 43 of 45 eyes (95.6%) and in 21 of 27 (77.8%) eyes in the low and moderate hyperopia groups, respectively. Only one eye (1.4%) from the moderate hyperopia group lost two lines of BCVA. Eighteen eyes (25%) required retreatment to correct residual hyperopia, 9 eyes (20.0%) in the low hyperopia group and 9 eyes (33.3%) in the moderate hyperopia group. Retreatments resulted in an MSE of +0.02 +/- 0.45 D and +0.04 +/- 0.73 D in the low and moderate hyperopia groups, respectively. No flap-related complications were seen. CONCLUSIONS: Hyperopic LASIK with the ACS and the Nidek EC-5000 excimer laser using our modified software is a safe, effective, and predictable procedure for low hyperopia. Results are satisfactory up to moderate hyperopia. Significant regression can occur for low and moderate hyperopia. Retreatment can be performed safely and effectively to improve the visual and refractive results.     

Five-year follow-up of laser in situ keratomileusis for hyperopia using the Technolas Keracor 117C excimer laser

PURPOSE: To evaluate safety, predictability, efficiency, and long-term stability of laser in situ keratomileusis (LASIK) for spherical hyperopia. METHODS: This study was a retrospective 5-year analysis of 67 patients (125 eyes) who had LASIK for spherical hyperopia; preoperative mean manifest spherical equivalent refraction was +3.84+/-1.13 D (range +1.00 to +6.50 D) and mean astigmatism was 0.37+/-0.27 D (range 0 to 1.00 D). Preoperative spherical equivalent refraction for the low hyperopia group was +1.00 to +2.75 D; medium hyperopia group, +3.00 to +4.25 D, and high hyperopia group, +4.50 to +6.50 D. All surgeries were performed using the scanning Chiron Technolas Keracor 117C excimer laser. Uncorrected and best spectacle-corrected visual acuity, predictability, long-term stability of refraction, and complications were analyzed. RESULTS: At 5 years after hyperopic LASIK, mean spherical equivalent refraction for the low hyperopia group was +0.48D+/-0.79 D; medium hyperopia group, +1.52+/-1.45 D; high hyperopia group C, +3.39+/-1.98 D. The percentage of eyes with a spherical equivalent refraction within +/-0.50 D of emmetropia for the low hyperopia group was 63% (37 eyes); medium hyperopia group, 42% (20 eyes); high hyperopia group, 22% (4 eyes). Eyes with chronic dry eye symptoms had a mean difference in spherical equivalent refraction from target refraction of +1.43 D compared with +0.84 D for eyes without dry eye symptoms. Five eyes (4%) lost 2 lines of BSCVA at 5 years. CONCLUSION: LASIK was safe, effective, and stable for primary hyperopia between +1.00 and +3.00 D. Higher amounts of hyperopia had poor long-term stability, especially eyes with more than +4.25 D. Chronic dry eye symptoms were associated with regression over time.     

Laser in situ keratomileusis using the Nidek EC-5000 or the Alcon LADARVision 4000 systems

PURPOSE: To compare the refractive results of eyes with low to moderate myopia that underwent laser in situ keratomileusis with either the Nidek EC-5000 or the Alcon LADARVision 4000 excimer laser systems. METHODS: We performed a retrospective review of 114 LASIK procedures with either the Nidek EC-5000 (54 eyes) or the Alcon LADARVision 4000 (60 eyes) excimer laser systems. Preoperative refractive errors were similar and both populations were treated during the same time period. Data analyzed included uncorrected visual acuity (UCVA), spherical magnitude, spherical equivalent refraction, astigmatism power, astigmatism axis, and vector astigmatism change. RESULTS: Results at 6 months were analyzed. Spherical correction change was a mean -3.95 D for Nidek treated eyes and a mean -4.53 D for LADARVision treated eyes (P = .20). Mean spherical equivalent refraction change was -3.70 D for Nidek eyes and -4.20 D for LADARVision eyes (P = .23). Mean change in UCVA (LogMAR) was 1.05 for Nidek eyes and 0.99 for LADARVision eyes (P = .40). Mean astigmatism magnitude change was 0.71 D for Nidek eyes and 0.77 D for LADARVision eyes (P = .63). Mean vector-corrected astigmatism change was 0.93 D for Nidek eyes and 1.00 D for LADARVision eyes (P = .63). Mean vector-corrected astigmatism axis for Nidek eyes was 3.08 D and for LADARVision eyes 6.58 D (P = .70). CONCLUSION: There was no significant difference in refractive results in eyes treated with the Alcon LADARVision 4000 or the Nidek EC-5000 excimer laser systems. Inherent differences between the two laser systems are highlighted.     

Laser in situ keratomileusus for mixed and simple myopic astigmatism with the Nidek EC-5000 Laser

PURPOSE: To evaluate the visual and refractive results of laser in situ keratomileusis (LASIK) for mixed and simple myopic astigmatism using bitoric ablation. METHODS: A retrospective study was performed in 65 eyes of 38 consecutive patients to evaluate uncorrected (UCVA) and best spectacle-corrected visual acuity (BSCVA) and cyclopegic and manifest refraction, before and 3 and 6 months after LASIK (Moria LSK-ONE microkeratome, Nidek EC-5000 excimer laser). RESULTS: At 3 and 6 months after LASIK, 40 eyes of 24 patients (64.5%) were available for follow-up examination. Mean age was 25.9 +/- 6.6 years (range 18 to 43 yr). Mean preoperative manifest spherical equivalent refraction was -1.40 +/- 0.80 D (range -3.80 to +0.50 D) mean preoperative cylinder was -3.30 +/- 1.30 D (range -1.00 to -6.00 D). At 6 months follow-up, mean manifest spherical equivalent refraction was +0.30 +/- 0.46 D (range -0.38 to +1.88 D), mean cylinder was -0.73 +/- 0.61 D (range -2.25 to 0 D). There was a 77.8% decrease in astigmatism magnitude. According to vector analysis, mean achieved vector magnitude was 80% of intended. Fifty percent (20 eyes) had a cylinder within +/- 0.50 D of emmetropia. Twenty-three eyes (57.5%) had a spherical component within +/- 0.50 D. Eighty-five percent (34 eyes) had postoperative UCVA of 20/40 or better. Ten percent (four eyes) lost two lines of Snellen BSCVA, whereas 35% (14 eyes) gained one or more lines. CONCLUSIONS: Bitoric LASIK with the Moria LSK-ONE microkeratome and Nidek EC-5000 excimer laser was effective and safe for the reduction of cylinder in mixed and simple myopic astigmatism. Moderate undercorrection of the cylinder was evident.     

Laser in situ keratomileusis for spherical hyperopia and hyperopic astigmatism using the NIDEK EC-5000 excimer laser

PURPOSE: To assess the efficacy, predictability, and safety of LASIK for the surgical correction of low to moderate hyperopia and hyperopic astigmatism using the NIDEK EC-5000 excimer laser. METHODS: In a multicenter United States Food and Drug Administration (FDA) regulated study of LASIK, 7 centers enrolled 293 eyes with manifest refraction sphere that ranged from +0.50 to +6.00 diopters (D) with or without astigmatism up to 3.00 D. The intended outcome was plano in all eyes. Patients were treated bilaterally. One year postoperative outcomes are reported. RESULTS: The mean spherical equivalent refraction (MRSE) for all eyes changed from +2.61 +/- 1.19 D (range: +0.50 to +6.63 D) preoperatively to +0.35 +/- 0.54 D (range: -1.63 to +2.00 D) 1 year postoperatively. Overall, 61% (170/279) of eyes achieved distance uncorrected visual acuity (UCVA) of 20/20 or better, 82% (228/279) of eyes saw 20/25 or better, and 99% (277/279) of eyes saw 20/40 or better. Refractive accuracy was demonstrated as 63.1% (176/279) of eyes achieved a MRSE within +/- 0.50 D and 90.3% (252/279) of eyes within +/- 1.00 D. Less than 2% (4/279) of eyes lost 2 lines of distance best spectacle-corrected visual acuity. Stability of refraction was demonstrated by 6 months, with a mean hyperopic shift of < 0.03 D from 3 to 6 months. CONCLUSIONS: The NIDEK EC-5000 corrected hyperopia and hyperopic astigmatism with UCVA, refractive accuracy, 1-year stability, and safety that surpassed all FDA criteria.     

Laser in situ keratomileusis for hyperopia and hyperopic astigmatism with the Nidek EC-5000 Excimer laser.

PURPOSE: We evaluated the efficacy, predictability, stability, and safety of laser in situ keratomileusis (LASIK) for hyperopia and hyperopic astigmatism. METHODS: A retrospective study was performed for 92 eyes of 62 consecutive patients to evaluate uncorrected (UCVA) and best spectacle-corrected visual acuity (BSCVA) and manifest refraction before and 3 and 6 months after LASIK (Moria LSK-ONE microkeratome, Nidek EC-5000 excimer laser). Eyes were divided into groups: Group 1 (low hyperopia) for spherical correction of +1.00 to +3.00 D (22 eyes), Group 2 (low hyperopic astigmatism) for toric correction with spherical equivalent refraction of +1.00 to +3.00 D (18 eyes), Group 3 (moderate hyperopia) for spherical correction of +3.25 to +6.00 D (10 eyes), and Group 4 (moderate hyperopic astigmatism) for toric correction with spherical equivalent refraction between +3.25 and +6.00 D (18 eyes). RESULTS: At 3 and 6 months after LASIK, 68 eyes (73.9%) were available for follow-up examination. Percentage of eyes with a spherical equivalent refraction within +/-0.50 D of emmetropia for Group 1 was 54.5% (12 eyes); Group 2, 50% (9 eyes); Group 3, 40% (4 eyes), and Group 4, 38.8% (7 eyes). UCVA > or =20/20 in Group 1 was 14% and in Groups 2, 3, and 4, 0%. One eye (5.5%) lost two lines of BSCVA. CONCLUSION: LASIK with the Moria LSK-ONE microkeratome and the Nidek EC-5000 excimer laser reduced low and moderate hyperopia and was within +/-0.50 D of target outcome in approximately 50% of eyes. Undercorrection was evident in all groups. The procedure was safe.     

Effect of expanding the treatment zone of the Nidek EC-5000 laser on laser in situ keratomileusis outcomes

PURPOSE: To evaluate the effect of expanding the treatment zone of the Nidek EC-5000 laser on postoperative visual acuity as well as night glare and halos after laser in situ keratomileusis (LASIK) using 4 ablation zone diameters. SETTING: Division of Ophthalmology, Evanston Northwestern Healthcare and Northwestern University Medical School, Glenview, Illinois, USA. METHODS: This prospective study comprised 301 eyes of 154 consecutive patients who had LASIK in 1 or both eyes using the Nidek EC-5000 laser by 1 surgeon with experience in keratomileusis and excimer laser refractive surgery. A 6.5 mm optical zone was used with a transition zone 1.0 mm larger than the pupil under scotopic conditions (7.5, 8.0, 8.5, or 9.0 mm). Targeted correction was calculated according to a customized clinical nomogram. All patients were queried about glare and halos preoperatively and 3 months postoperatively using a questionnaire assigning numeric values to the degree of perceived visual disturbance (0 = no glare or halos, 1 = minimal, 2 = moderate, 3 = severe). RESULTS: The baseline uncorrected visual acuity (UCVA) was 20/200 or worse in 293 eyes. The baseline best spectacle-corrected visual acuity was 20/20 or better. The mean preoperative refractive sphere was -6.33 diopters (D) +/- 2.80 (SD) (range -1.00 to -16.25 D) and the mean preoperative refractive cylinder, 0.86 +/- 0.83 D (range 0 to +3.25 D). Three months postoperatively, 78% of eyes had a UCVA of 20/20 and 99%, of 20/40 or better. Preoperatively, 94 eyes (31%) had glare and halos. At 3 months, glare, halos, or both were present in 19 eyes of 11 patients (6.3%) (P<.0001); in 14 eyes, patients reported less severe glare and halos postoperatively than preoperatively. CONCLUSIONS: The use of a peripheral transition zone 1.0 mm larger than the pupil under scotopic conditions resulted in a low incidence of glare and halos postoperatively and did not adversely affect visual acuity. There was no increase in postoperative complications including corneal ectasia.     

Analysis of the efficacy, predictability, and safety of LASEK for myopia and myopic astigmatism using the Technolas 217 excimer laser

PURPOSE: To evaluate the efficacy, predictability, and safety of laser-assisted subepithelial keratectomy (LASEK) for the treatment of myopia and myopic astigmatism. SETTING: Stanford University Eye Laser Center, Stanford, California, USA. METHODS: This retrospective analysis comprised 102 eyes that had LASEK for myopia using the Bausch & Lomb Technolas 217 excimer laser. Primary outcome variables including uncorrected visual acuity (UCVA), best spectacle- corrected visual acuity (BSCVA), manifest refraction, and complications were evaluated at 3, 6, and 12 months. Vector analysis was performed on eyes that received astigmatic correction. RESULTS: The mean spherical equivalent was -7.03 diopters (D) +/- 2.61 (SD) preoperatively, +0.19 +/- 0.64 D at 3 months, +0.23 +/- 0.82 D at 6 months, and +0.03 +/- 0.63 D at 12 months (P<.001). At 3, 6, and 12 months, the UCVA was 20/20 or better in 66%, 67%, and 83% of eyes, respectively, and 20/40 or better in 98%, 99%, and 100%; 74%, 70%, and 83%, respectively, were within +/-0.5 D of emmetropia, and 89%, 86%, and 97%, respectively, were within +/-1.0 D. No eye lost more than 2 lines of BSCVA. At 3, 6, and 12 months, 10.0%, 8.7%, and 0% of eyes, respectively, had trace corneal haze. Vector analysis found a success rate of approximately 78% to 80% in achieving the astigmatic surgical correction at the 3 postoperative visits. CONCLUSIONS: Laser-assisted subepithelial keratectomy was an effective, predictable, and safe procedure for the treatment of myopia and myopic astigmatism. Further studies are needed to determine the role of LASEK in the refractive surgery spectrum.     

Technolas 217z准分子激光角膜组织切削深度预测性的评价

目的评价Technolas 217z准分子激光机角膜组织切削深度的预测性。方法采用Technolas 217z准分子激光机对近视眼患者进行治疗,将患者分为标准化切削LASIK组(planoscan-Lasik,P组),个性化切削LASIK组(Zyoptix,Z组)以及LASEK组(planoscan-Lasek,E组)。手术中用DGH超声测厚仪分别在手术前,激光治疗前和激光治疗后测量角膜厚度,计算出实际激光切削量,与预测理论切削深度进行对比,采用单因素方差分析对组间差别进行比较,分别计算三组理论切削深度值与实际切削深度之间的直线回归方程,并作相关系数的检验。结果Technolas217z准分子激光在P组预测组织切削深度为(102.04±33.46)um,实际组织切削深度为(129.41±38.96)um,实际切削深度较预测切削深度增加(27.37±18.02)um,两者差异有统计学意义(P<0.01);在Z组,预测组织切削深度为(115.59±23.29)um,实际组织切削深度为(149.18±30.73)um,实际切削深度较预测切削深度增加(33.59±19.98)um,两者差异差异有统计学意义(P<0.01);而E组,预测组织切削深度为(106.96±18.43)um,实际组织切削深度为(111.12±18.73)um,较预测切削深度增加(4.16±2.89)um,经统计学处理,两者差异无统计学意义(P=0.164);在三组中,实际组织切削深度与预测切削深度均具有较好的相关性,其直线回归方程分别为y=34.45 0.762x(P组),y=29.698 0.576x(Z组),y=31.707 0.679x(E组)。结论Tachnolas 217z准分子激光在标准化和个性化Lasik手术中实际组织切削深度均较预测深度增加,而在Lasek手术中其预测切削深度与实际深度一致性较好,设计手术方案时应将这一因素考虑进去,对于Lasik手术将角膜基质床厚度留在280um以上更为合适,而对于角膜偏薄的患者,采用LASEK手术具有更高的安全性。     

Comparison of photorefractive keratectomy and laser in situ keratomileusis for myopia of -6 D or less using the Nidek EC-5000 laser

PURPOSE: We compared the efficacy, predictability, and safety of photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK) for the surgical correction of low and moderate myopia. METHODS: A retrospective study was performed to evaluate uncorrected and spectacle-corrected visual acuity, and manifest refraction 1 year after PRK or LASIK. All procedures were done using an automatic microkeratome (Chiron Ophthalmic) and the Nidek EC-5000 excimer laser. RESULTS: PRK was performed in 75 eyes of 45 patients and LASIK in 133 eyes of 77 patients. Mean age for PRK patients was 32.8 years (range, 18 to 52 yr) and LASIK patients was 29.6 years (range, 18 to 49 yr). Mean preoperative spherical equivalent refraction for PRK patients was -3.28 D (range, -1.00 to -6.00 D) and LASIK, -3.86 D (range, -1.00 to -6.00 D). One year after surgery, mean spherical equivalent refraction for Group 1 (baseline, -1.00 to -3.00 D) PRK eyes was -0.18 +/- 0.61 D (range, -1.50 to +0.75 D) and for LASIK eyes, -0.08 +/- 0.61 D (range, -1.50 to +1.62 D), with no statistically significant difference. For Group 2 eyes (baseline, -3.25 to -6.00 D), mean spherical equivalent refraction for PRK eyes was -0.44 +/- 0.87 D (range, -2.00 to +2.12 D) and for LASIK eyes, -0.09 +/- 0.83 D (range, -1.50 to +1.75 D), with no statistically significant difference. The antilogarithm of the mean UCVA (antilogUCVA) in Group 1 for PRK was 0.79 +/- 0.21 (20/25) and for LASIK was 0.87 +/- 0.19 (20/23), with no statistically significant difference. The antilogUCVA in Group 2 for PRK eyes was 0.70 +/- 0.24 (20/28) and for LASIK eyes was 0.83 +/- 0.18 (20/24), with a statistically significant difference (0.7 vs. 0.83, P < .005). The percentage of eyes with a postoperative UCVA >20/40 in Group 1 for PRK was 91.5% (38 eyes) and for LASIK was 95% (50 eyes) (no statistically significant difference), and in Group 2 for PRK eyes, it was 82% (27 eyes) and 97.5% (78 eyes) for LASIK (statistically significant difference, P < .05). CONCLUSION: PRK and LASIK with the Nidek EC-5000 excimer laser are effective and safe for correcting low to moderate myopia, but LASIK eyes showed better results for moderate myopia in terms of uncorrected visual acuity.     

Laser in situ keratomileusis for myopia and compound myopic astigmatism using the Technolas 217 scanning-spot laser

PURPOSE: To evaluate the safety, efficacy, predictability, and visual results of laser in situ keratomileusis (LASIK) using the Bausch & Lomb Technolas(R) 217 scanning-spot laser for the treatment of myopia and compound myopic astigmatism. SETTING: Stanford Eye Laser Center, Stanford, California, USA. METHODS: In a prospective study, 110 eyes of 58 patients with a mean spherical equivalent (SE) of -4.87 diopters (D) +/- 2.5 (SD) (range -1.0 to -11.4 D) had LASIK for myopia and compound myopic astigmatism using the Technolas 217 scanning-spot laser. The primary outcome variables included preoperative and postoperative best spectacle-corrected visual acuity (BSCVA), uncorrected visual acuity (UCVA), achieved versus attempted correction, vector analysis of astigmatism, and complications. RESULTS: One hundred ten eyes were available for analysis at 3 months. The mean SE refraction was reduced 95% (mean -0.23 +/- 0.4 D), and astigmatism was reduced 70% (mean 0.28 +/- 0.3 D). One day postoperatively, 100% of eyes had a UCVA of 20/40 or better, 96% had 20/25 or better, 77% had 20/20 or better, and 39% had 20/15 or better. At the 3-month examination, 100% of eyes had a UCVA of 20/40 or better, 95% had 20/25 or better, 83% had 20/20 or better, and 48% had 20/15 or better. Ninety percent of eyes were within +/-0.5 D of emmetropia. No eye lost 2 or more lines of BSCVA. CONCLUSIONS: The Technolas 217 scanning-spot laser produced excellent postoperative UCVA and BSCVA. It was predictable, safe, and effective for the treatment of myopia and compound myopic astigmatism. Long-term follow-up is needed to assess the stability of the procedure.     

Geometric customization of optical and transition zone parameters for treatment of compound myopic astigmatism with the NIDEK EC-5000 excimer laser

PURPOSE: To compare the refractive outcome of two ablation zone designs using LASIK for the correction of compound myopic astigmatism. METHODS: This retrospective study compared refractive outcomes in two groups of patients undergoing LASIK. In the circular treatment group, 45 eyes were corrected with circular optical and transition zones of 6 mm and 6.5 mm, respectively. In the customized treatment group, 45 eyes were corrected with optical and transition zones enlarged along the flat axis to 6.5 mm and 7.5 mm, respectively. P values <.05 were considered statistically significant. RESULTS: Mean preoperative spherical equivalent refraction was -5.36+/-2.02 diopters (D) and -5.36+/- 2.13 D for the circular and customized treatment groups, respectively. Mean postoperative spherical equivalent refraction was -0.09+/-0.74 D and -0.11+/-0.42 D for the circular and customized treatment groups, respectively. Mean cylinder was 0.49+/-0.39 D and 0.22+/-0.43 D for the circular and customized treatment groups, respectively (P<.001). Postoperative blur strength index was 0.68+/-0.44 D and 0.39+/-0.27 D in the circular and customized treatment groups, respectively (P<.001). Uncorrected visual acuity was significantly better in the customized treatment group compared with the circular treatment group (P<.05). The gain in lines of best spectacle-corrected visual acuity was significantly greater in the customized treatment group compared with the circular treatment group (P<.001). CONCLUSIONS: An elliptical ablation zone for treating compound myopic astigmatism results in better efficacy, safety, and lower tissue removal than a circular treatment zone. This may be due to the geometric optimization provided by the enlargement of the optical and transition zones along the flat meridian.     

准分子激光近视矫正术后角膜前表面形态变化的研究

目的:探讨准分子激光角膜屈光手术前后角膜前表面形态的改变。方法:95只近视眼分为中/低度近视组(A组,n=53)和高度近视组(B组,n=42),角膜地形图测量并记录手术前后角膜Q值并进行统计学分析。结果:所有术眼手术前后角膜Q值有显著差异(P<0.01)。术前角膜Q值两组间没有统计学差异(P>0.05),术前屈光度与角膜Q值没有相关性(P>0.05)。但术后角膜Q值在两组间有显著差异(P<0.01)。B组手术前后角膜Q值变化的绝对值大于A组(P<0.01),术后角膜Q值变化与术前屈光度的大小呈显著正相关(P<0.01)。结论:准分子激光角膜屈光手术后角膜前表面形态发生显著改变,由术前长椭圆非球面形(Prolate)变为扁椭圆非球面形(Oblate)。高度近视组手术后角膜前表面形态改变程度大于中/低近视组。     

Laser in situ keratomileusis for the correction of hyperopia from +1.25 to +5.00 diopters with the Technolas Keracor 117C laser

PURPOSE: To assess the efficacy, predictability, stability, and safety of laser in situ keratomileusis (LASIK) in patients with hyperopia and to evaluate the visual and refractive results of the procedure. METHODS: LASIK was performed on 85 eyes of 53 patients for correction of hyperopia, with a preoperative mean manifest spherical equivalent refraction of +3.31 +/- 0.69 D (range, +1.25 to +5.00 D) and mean refractive astigmatism of +0.91 +/- 1.06 D (range, 0 to +3.00 D). The Carriazo-Barraquer (Moria) manual microkeratome was used to create the corneal flap, and laser ablation was performed using the Technolas Keracor 117C excimer laser with an ablation zone diameter of 6.0 mm and a transition zone diameter to 9.0 mm. Follow-up was 12 months for all patients. RESULTS: Refraction was stable by 3 months after surgery. At 1 year after LASIK, the mean manifest spherical equivalent refraction was +0.43 +/- 0.57 D (range, -1.25 to +2.00 D) and refractive astigmatism was reduced to a mean of 0.36 +/- 0.30 D (range, 0 to 1.00 D). Fifty-two eyes (61.2%) had a manifest spherical equivalent refraction within +/- 0.50 D of emmetropia, and 76 eyes (89.4%) were within +/- 1.00 D. Uncorrected visual acuity was 20/20 in 21 eyes (24.7%) and 20/40 or better in 79 eyes (92.9%). Spectacle-corrected visual acuity was reduced by two lines in one eye (1.2%) and improved by two lines in five eyes (5.9%). There were no significant complications. CONCLUSION: LASIK was an effective, safe, and predictable procedure for the correction of hyperopia up to +5.00 D and hyperopic astigmatism up to +3.00 D with the Technolas Keracor 117C excimer laser. The large size of the corneal flap obtained by the Carriazo-Barraquer (Moria) manual microkeratome facilitated laser ablation entirely in the exposed corneal stromal bed.     

Correction of presbyopia in hyperopia with a center-distance, paracentral-near technique using the Technolas 217z platform

PURPOSE: To analyze the results of hyperopic patients treated with a peripheral presbyLASIK algorithm for the correction of presbyopia. METHODS: The study included 44 eyes of 22 hyperopic patients treated with a peripheral presbyLASIK technique using a Technolas 217z excimer laser. Mean patient age was 56 years (range: 47 to 72 years), mean preoperative spherical equivalent refraction was +1.21 +/- 0.77 diopters (D) (range: +0.50 to +4.00 D), and mean spectacle near addition was +1.76 +/- 0.42 D (range: +1.00 to +2.75 D). The Peripheral Multifocal LASIK (PML) ablation pattern creates a multifocal corneal profile over a 6.5-mm diameter, performing the distance correction first in a 6-mm optical zone and then near correction in a 6.5-mm zone. Main outcome measures were uncorrected visual acuity (UCVA) and best spectacle-corrected visual acuity (BSCVA) for near and distance, spherical equivalent refraction, contrast sensitivity, and corneal aberrations. RESULTS: Six months postoperatively, mean binocular UCVA was 1.06 +/- 0.13 for distance and 0.84 +/- 0.14 for near. Mean postoperative spherical equivalent refraction was -0.42 D (range: -1.12 to +0.87 D). Two (4.5%) eyes lost 1 line of BSCVA for distance and near vision, and 20 (45%) eyes gained 1 line of distance BSCVA. Contrast sensitivity decreased for 3, 6, 12, and 18 cycles/degree. Corneal aberration analysis showed a slight increase in coma and decrease in spherical aberration. CONCLUSIONS: The peripheral presbyLASIK technique used in this study is a safe and efficient treatment that may improve functional near vision in presbyopic patients with low and moderate hyperopia (from +0.50 to +3.00 D).     

Influence of excimer laser photorefractive keratectomy on the posterior corneal surface

PURPOSE: To investigate the influence of excimer laser photorefractive keratectomy on the refraction and geometry of the posterior corneal surface. SETTING: Miyata Eye Hospital, Miyazaki, Japan. METHODS: Thirty-seven eyes of 21 patients with refractive errors of -2.00 to -9.75 diopters (D) were treated with the VISX Twenty-Twenty excimer laser system. The refractive and anteroposterior changes in the posterior corneal surface were measured using scanning-slit corneal topography (Orbscan, Orbtek, Inc.) preoperatively and 1 week and 1 and 3 months postoperatively. RESULTS: Mean posterior corneal refraction was -6.51 D +/- 0. 29 (SD) preoperatively; it decreased to -7.00 +/- 0.49 D, -7.00 +/- 0.55 D, and -6.92 +/- 0.42 D at 1 week, 1 month, and 3 months, respectively (P <.001, Tukey multiple comparison). Mean forward shift of the posterior corneal surface was 29.5 +/- 1.9 microm, 34.4 +/- 3.4 microm, and 54.3 +/- 4.0 microm at 1 week, 1 month, and 3 months, respectively. The amount of posterior corneal refractive change correlated with the degree of forward shift (r= -0.691, P <. 001). The residual corneal thickness correlated with the refractive change (r = 0.524, P <.001) and the forward shift (r = -0.851, P <. 001) of the posterior corneal surface. CONCLUSION: Photorefractive keratectomy induced significant refractive changes in the posterior corneal surface and forward shift of the cornea, both of which correlated with the thinness of the residual cornea.     

Mitomycin C in refractive corneal surface surgery with the excimer laser: first experience and review of the literature

Haze formation with loss of corneal transparency and surface irregularities and myopic regression are the major complications after corneal refractive surface surgery. The use of mitomycin C (MMC) with its antibiotic and antineoplastic properties is intended to inhibit wound healing mechanisms leading to subepithelial fibrosis. We report the use of MMC to achieve visual rehabilitation in the re-treatment of 3 eyes of 2 patients following refractive corneal surgery. According to the literature, the local use of MMC 0.02 % for 2 minutes is safe and enables one to treat and prevent stromal haze and myopic regression and allows a reduction of the postoperative topical pharmacotherapy. Results are still limited due to small case numbers and short follow-up periods.